HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.109.064659v1 51/1/92    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tekabe, Y. Articles by Johnson, L. L. Search for Related Content PubMed PubMed Citation Articles by Tekabe, Y. Articles by Johnson, L. L.

A Novel Monoclonal Antibody for RAGE-Directed Imaging Identifies Accelerated Atherosclerosis in Diabetes

¹ Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York; and ² Division of Surgical Science, Department of Surgery, Columbia University Medical Center, New York, New York

Correspondence: For correspondence or reprints contact: Yared Tekabe, Division of Cardiology, Department of Medicine, Columbia University Medical Center, 620 W. 168 St., New York, NY 10032. E-mail: yt2166{at}columbia.edu

Receptor for advanced glycation end products (RAGE) binds advanced glycation end products and other inflammatory ligands and is expressed in atherosclerotic plaques in diabetic and nondiabetic subjects. The higher expression in diabetes mellitus corresponds to the accelerated course of the atherosclerosis. This study was designed to test the hypothesis that the level of RAGE expression in atherosclerosis can be detected by quantitative in vivo SPECT and that counts in the target will correlate with the strength of the biologic signal. Methods: A monoclonal murine antibody was developed against the V-domain of RAGE, fragmented into F(ab')₂ and labeled with ^99mTc, and injected at a dose of 15.14 ± 1.23 MBq into 24-wk-old male apolipoprotein E null (ApoE^–/–) mice (n = 22), including mice with streptozotocin-induced diabetes mellitus (n = 8), nondiabetic mice (n = 8), and control ApoE^–/–/RAGE^–/– double-knock-out mice (n = 6). Four hours later (allowing for blood-pool clearance), the mice were imaged and sacrificed, and the proximal aorta was removed and counted to calculate the percentage injected dose of RAGE per gram of tissue, followed by histologic and immunohistochemical characterization. Results: Radiotracer uptake in the aortic lesions was clearly visualized noninvasively by SPECT. RAGE uptake as percentage injected dose in diabetic ApoE^–/– mice (1.39 ± 0.16 x 10^–2) was significantly higher than that in nondiabetic ApoE^–/– mice (0.48 ± 0.27 x 10^–2) (P < 0.0001). The radiotracer uptake was highly correlated with RAGE expression by quantitative immunohistomorphometry (r = 0.82, P = 0.002) and with percentage of macrophages (r = 0.86, P < 0.0001). Conclusion: In this study, ^99mTc-labeled anti-RAGE F(ab')₂ SPECT successfully identified early accelerated disease in diabetes mellitus for age-matched ApoE^–/– mice and quantified RAGE expression over a range of lesion severities.

Key Words: ApoE^–/– mice • atherosclerosis • diabetes • RAGE

COPYRIGHT © 2010 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2010 51: 9A-10A. [Full Text]